Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab + AZA vs AZA in Higher-risk MDS
NCT05709093Phase 3Terminated
- Sponsor
- TJ Biopharma
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lemzoparlimab in myelodysplastic syndrome (MDS), sponsored by TJ Biopharma. Started Mar 2023; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05709093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709093.